Erik Robert Hartmann


Erik has over 30 years of Investment Banking experience. He is specialized in the origination of M&A transactions and pharmaceutical business development. Erik is a Board Member and advisor of international companies and Life Sciences related Funds, as such Erik has a deep knowledge within the Pharma and Biotech industries. He speaks fluently English, German and Spanish.


Erik is a member of various Boards of Latin American companies, advisor to Adium Pharma, Montevideo, Uruguay. He is Vice Chairman of Perutil an Investment Fund, based in Panama. He participates in a public educational project in Montevideo, Uruguay, Fundación Retoño.

In 1984, Erik joined J.P. Morgan where he worked in the Zurich and New York offices, in commercial banking and investment banking management positions.

Since 1990 Erik R. Hartmann works in the pharmaceutical industry, he is responsible for licensing and business development in Tecnofarma, a major Latin American pharmaceutical group.

Erik has also negotiated important corporate partnerships with multinational pharmaceutical and biotechnology companies such as Amgen Inc., USA; Celgene Corporation, USA; Astellas Pharma, Chicago USA and Novartis, Switzerland. He originated and advised in a major acquisition by Novartis (Sandoz) in Argentina.


Born in 1957, Erik obtained his Master of Economics at the University of St. Gallen in Switzerland. 

Life drives and passions

Philosophy, golf, tennis, opera

Montevideo, Uruguay